Preclinical research on SCLC cells and SCLC GEMMs, as well as genomic analyses of SCLC tumors derived from patients, reveal that these two genes are the most frequently mutated and support the notion that the inactivation of p53 and Rb is the catalytic step in the development of SCLC. The gene discussed is RB1; the disease is small cell lung carcinoma.